"In these OAC-naive patients, asundexian was associated with a slight increase in stroke rates but demonstrated a lower risk ...

A lower apixaban dose is indicated in patients with an eGFR less than 30 mL/min/1.73 m2, regardless of dialysis status.

Perspective from Geoffrey Barnes, MD, MSc CHICAGO — For patients with cancer requiring extended anticoagulant therapy, a strategy of reduced-dose apixaban was noninferior to full-dose apixaban ...

Although international guidelines suggest that anticoagulant treatment be continued ... Participants were randomized to oral apixaban at a reduced dose (2.5 mg) or a full dose (5.0 mg) twice ...

The API-CAT (Apixaban Cancer Associated Thrombosis ... or pulmonary embolism who had completed at least 6 months of anticoagulant therapy without documented symptomatic recurrence.

“Best known as a trusted nausea remedy, ginger tea has a spicy and full-bodied flavour,” they said. “It contains the ...

Two Phase III trials found that apixaban was more effective for stroke prevention than either aspirin or warfarin in patients with atrial fibrillation (AF), with a similar (versus aspirin ...

However, studies also show that anticoagulant treatment may increase ... the API-CAT trial was to assess whether the lower dose of apixaban was comparable to the full dose in preventing VTE ...

with active cancer and proximal deep vein thrombosis or pulmonary embolism who’d been on at least 6 months of anticoagulant therapy. Patients were randomized in a double-blind fashion to receive 2.5 ...

In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant ... a 1:1 ratio to receive oral apixaban at a reduced (2.5 ...